291 related articles for article (PubMed ID: 37882914)
41. Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior.
Chan LF; Eu CL; Soh SY; Maniam T; Shahidii Kadir Z; Chong BTW; Loo JL; Sharip S; Wong VCW; Loo TH; Ng YP; Kahn DA
J Psychiatr Pract; 2018 Jul; 24(4):279-291. PubMed ID: 30427812
[TBL] [Abstract][Full Text] [Related]
42. Treatment patterns in patients with treatment-resistant depression in Danish patients with major depressive disorder.
Gronemann FH; Petersen J; Alulis S; Jensen KJ; Riise J; Ankarfeldt MZ; Solem EJ; Bødker N; Osler M
J Affect Disord; 2021 May; 287():204-213. PubMed ID: 33799039
[TBL] [Abstract][Full Text] [Related]
43. Investigation of early and lifetime clinical features and comorbidities for the risk of developing treatment-resistant depression in a 13-year nationwide cohort study.
Huang SS; Chen HH; Wang J; Chen WJ; Chen HC; Kuo PH
BMC Psychiatry; 2020 Nov; 20(1):541. PubMed ID: 33203427
[TBL] [Abstract][Full Text] [Related]
44. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials.
Berlim MT; Turecki G
Eur Neuropsychopharmacol; 2007 Nov; 17(11):696-707. PubMed ID: 17521891
[TBL] [Abstract][Full Text] [Related]
45. Novel drug developmental strategies for treatment-resistant depression.
Borbély É; Simon M; Fuchs E; Wiborg O; Czéh B; Helyes Z
Br J Pharmacol; 2022 Mar; 179(6):1146-1186. PubMed ID: 34822719
[TBL] [Abstract][Full Text] [Related]
46. Antidepressant-resistant depression is characterized by reduced short- and long-interval cortical inhibition.
Jeng JS; Li CT; Lin HC; Tsai SJ; Bai YM; Su TP; Chang YW; Cheng CM
Psychol Med; 2020 Jun; 50(8):1285-1291. PubMed ID: 31155020
[TBL] [Abstract][Full Text] [Related]
47. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C
J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416
[TBL] [Abstract][Full Text] [Related]
48. Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".
Borentain S; Desai P; Fu DJ; Nancy Chen L; Lane R; Mathews M; Canuso CM
J Psychopharmacol; 2023 Aug; 37(8):836-844. PubMed ID: 36218274
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
[TBL] [Abstract][Full Text] [Related]
50. Inflammatory markers and treatment outcome in treatment resistant depression: A systematic review.
Yang C; Wardenaar KJ; Bosker FJ; Li J; Schoevers RA
J Affect Disord; 2019 Oct; 257():640-649. PubMed ID: 31357161
[TBL] [Abstract][Full Text] [Related]
51. Recovering from depression with repetitive transcranial magnetic stimulation (rTMS): a systematic review and meta-analysis of preclinical studies.
De Risio L; Borgi M; Pettorruso M; Miuli A; Ottomana AM; Sociali A; Martinotti G; Nicolò G; Macrì S; di Giannantonio M; Zoratto F
Transl Psychiatry; 2020 Nov; 10(1):393. PubMed ID: 33173042
[TBL] [Abstract][Full Text] [Related]
52. Therapy of treatment resistant depression: focus on the management of TRD with atypical antipsychotics.
Klein N; Sacher J; Wallner H; Tauscher J; Kasper S
CNS Spectr; 2004 Nov; 9(11):823-32. PubMed ID: 15520606
[TBL] [Abstract][Full Text] [Related]
53. Novel antidepressant drugs: Beyond monoamine targets.
Gonda X; Dome P; Neill JC; Tarazi FI
CNS Spectr; 2023 Feb; 28(1):6-15. PubMed ID: 34588093
[TBL] [Abstract][Full Text] [Related]
54. Definition of treatment-resistant depression - Asia Pacific perspectives.
Ng CH; Kato T; Han C; Wang G; Trivedi M; Ramesh V; Shao D; Gala S; Narayanan S; Tan W; Feng Y; Kasper S
J Affect Disord; 2019 Feb; 245():626-636. PubMed ID: 30445388
[TBL] [Abstract][Full Text] [Related]
55. A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom.
Denee T; Ming T; Waller J; Bailey T; Rajkovic-Hooley O; Middleton-Dalby C; Le HH; Zhang Q; McCrone P; Taylor D
Curr Med Res Opin; 2021 Feb; 37(2):311-319. PubMed ID: 33253055
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.
Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M
J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333
[TBL] [Abstract][Full Text] [Related]
57. Copper and anti-anhedonic effect of ketamine in treatment-resistant depression.
Słupski J; Cubała WJ; Górska N; Słupska A; Gałuszko-Węgielnik M
Med Hypotheses; 2020 Nov; 144():110268. PubMed ID: 33254572
[TBL] [Abstract][Full Text] [Related]
58. Ketamine: Future Treatment For Unresponsive Depression?
Frere M; Tepper J
Ir Med J; 2016 Sep; 109(8):453. PubMed ID: 28124853
[TBL] [Abstract][Full Text] [Related]
59. Ketamine supresses REM sleep and markedly increases EEG gamma oscillations in the Wistar Kyoto rat model of treatment-resistant depression.
Kantor S; Lanigan M; Giggins L; Lione L; Magomedova L; de Lannoy I; Upton N; Duxon M
Behav Brain Res; 2023 Jul; 449():114473. PubMed ID: 37146722
[TBL] [Abstract][Full Text] [Related]
60. Courses of treatment and risk factors for treatment-resistant depression in Finnish primary and special healthcare: A nationwide cohort study.
Lähteenvuo M; Taipale H; Tanskanen A; Rannanpää S; Tiihonen J
J Affect Disord; 2022 Jul; 308():236-242. PubMed ID: 35398108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
